Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Engineered EVs from 3D-Cultured MSCs for Synergistic Modulation of Inflammatory Microenvironment and Cartilage Regeneration in Osteoarthritis.

Fu S., Wang Y., Zhou J., Liu Y., Wan J., Xu L.

Animal Study on Osteoarthritis, Cartilage Damage, Chronic Inflammation, published in ACS Appl Mater Interfaces (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
ACS Appl Mater Interfaces (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40673894
DOI
10.1021/acsami.5c06750

Abstract (original English)

Osteoarthritis (OA) is a common and serious joint disease characterized by synovitis and articular cartilage degeneration. Effective nonsurgical treatments for OA are still lacking. In this study, we designed an injectable temperature-sensitive hydrogel system delivering engineered extracellular vesicles for the treatment of OA. We increased the yield and efficacy of extracellular vesicles by three-dimensional(3D) culture of adipose mesenchymal stem cells. The anti-inflammatory drug celecoxib was then loaded into the extracellular vesicles via electroporation, resulting in the construction of engineered extracellular vesicles (CEVs) with both anti-inflammatory and cartilage regeneration functions. An injectable thermosensitive hydrogel was prepared with Pluronic F127 (F127) and hyaluronic acid (HA) for the delivery of CEVs, thereby forming a composite treatment system (CEVs@F127-HA). CEVs@F127-HA could inhibit M1-type macrophage polarization, protect the metabolic homeostasis of chondrocytes, and promote the differentiation of bone marrow mesenchymal stem cells (BMSCs) into chondrocytes in vitro . CEVs@F127-HA also prolonged the retention time of CEVs in the joint cavity and provided long-term synergistic therapeutic benefits. In vivo experiments utilizing a sodium iodoacetate-induced OA mouse model also demonstrated that CEVs@F127-HA could effectively reduce joint inflammation

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsOsteoarthritisMiceExtracellular VesiclesCartilage, ArticularCelecoxibRegenerationHydrogelsHyaluronic Acid

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research